SCHEMBL4036129

SCHEMBL4036129

CCCC(C)CCC(=O)OCC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.49
KMT2A Q03164 2/20 0.46
POLB P06746 2/20 0.46
CYP1A2 P05177 1/20 0.45
GAA P10253 2/20 0.44
MGAM O43451 1/20 0.44
SI P14410 1/20 0.44
MGAM2 Q2M2H8 1/20 0.44
ALDH1A1 P00352 4/20 0.41
TRPA1 O75762 1/20 0.41
TSHR P16473 3/20 0.39
MAPT P10636 2/20 0.39
CYP4F2 P78329 2/20 0.38
CYP4A11 Q02928 2/20 0.38
CYP3A4 P08684 1/20 0.38
ATM Q13315 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
NR1I2 O75469 1/20 0.37
PGR P06401 1/20 0.37
ADORA3 P0DMS8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL434247 0.88 KMT2A (0.47) L3MBTL1KMT2APOLBCYP1A2GAA
SCHEMBL9779602 0.86 ACE2 (0.50) L3MBTL1KMT2APOLBCYP1A2ALDH1A1
SCHEMBL18803112 0.86 DGKA (0.44) L3MBTL1POLBALDH1A1TSHRMAPT
SCHEMBL11652884 0.86 GABRP (0.48) L3MBTL1KMT2APOLBCYP1A2GAA
SCHEMBL8410329 0.85 L3MBTL1 (0.50) L3MBTL1KMT2APOLBCYP1A2GAA
SCHEMBL18561876 0.85 L3MBTL1 (0.50) L3MBTL1KMT2APOLBCYP1A2GAA
SCHEMBL8410331 0.85 L3MBTL1 (0.50) L3MBTL1KMT2APOLBCYP1A2GAA
SCHEMBL29134114 0.85 ACE2 (0.53) L3MBTL1KMT2APOLBCYP1A2ALDH1A1
SCHEMBL2245530 0.84 CYP1A2 (0.52) L3MBTL1KMT2APOLBCYP1A2GAA
SCHEMBL6067665 0.83 L3MBTL1 (0.49) L3MBTL1KMT2APOLBCYP1A2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025096734-A1 MICROCAPSULES FMC CORPORATION (US) 2025-05-08 WO disclosed
CN-109810589-A Light converts resin combination, light conversion layer folds substrate and image display device 东友精细化工有限公司 2019-05-28 CN disclosed
US-9981903-B2 Method for preparing di- or tricarboxylic esters by alkoxycarbonylation of dienes having conjugated double bonds EVONIK DEGUSSA GMBH (DE) 2018-05-29 US disclosed
CN-105622416-B The preparation method for the compound that a kind of fluorene group and carboxylate combine 中国石油化工股份有限公司 2018-05-11 CN disclosed
US-20180022687-A1 METHOD FOR PREPARING DI- OR TRICARBOXYLIC ESTERS BY ALKOXYCARBONYLATION OF DIENES HAVING CONJUGATED DOUBLE BONDS EVONIK DEGUSSA GMBH (DE) 2018-01-25 US disclosed
EP-1444211-B1 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS ASTRAZENECA AB (SE) 2009-01-21 EP disclosed
US-20070088044-A1 Quinazoline derivatives as antitumor agents ASTRAZENECA AB 2007-04-19 US disclosed
CN-1764651-A Quinazoline derivatives as antitumor agents ASTRAZENECA AB (SE) 2006-04-26 CN disclosed
US-6953809-B2 Monocyte chemoattractant protein-1 inhibitor compounds ZENECA LIMITED (GB) 2005-10-11 US disclosed
US-20050054662-A1 Quinazoline derivatives as antitumor agents ASTRAZENECA AB (SE) 2005-03-10 US disclosed
CN-1291094-A Bicyclic pyrrole derivatives as MCP-1 inhibitor ASTRA ZENECA BRITISH CO LTD (GB) 2001-04-11 CN disclosed
EP-1056451-A1 BICYCLIC PYRROLE DERIVATIVES AS MCP-1 INHIBITORS AstraZeneca UK Limited (GB) 2000-12-06 EP disclosed
EP-1054667-A1 BICYCLIC PYRROLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANTIINFLAMMATORY AND IMMUNOMODULATING AGENTS AstraZeneca UK Limited (GB) 2000-11-29 EP disclosed
CN-1265591-A Coumpound ZENECA LTD (GB) 2000-09-06 CN disclosed
EP-1003504-A2 INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS AstraZeneca UK Limited (GB) 2000-05-31 EP disclosed
EP-1001935-A1 INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS ZENECA LIMITED (GB) 2000-05-24 EP disclosed
WO-1999040914-A1 BICYCLIC PYRROLE DERIVATIVES AS MCP-1 INHIBITORS ASTRAZENECA UK LIMITED (GB) 1999-08-19 WO disclosed
WO-1999040913-A1 CHEMICAL COMPOUNDS ASTRAZENECA UK LIMITED (GB) 1999-08-19 WO disclosed
WO-1999007678-A1 INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS ZENECA LIMITED (GB) 1999-02-18 WO disclosed
WO-1999007351-A2 INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS ZENECA LIMITED (GB) 1999-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180022687-A1 METHOD FOR PREPARING DI- OR TRICARBOXYLIC ESTERS BY ALKOXYCARBONYLATION OF DIENES HAVING CONJUGATED DOUBLE BONDS C9, PC, CBR3 L3MBTL1 760/4885KMT2A 2960/4885POLB 1033/4885
US-20050054662-A1 Quinazoline derivatives as antitumor agents ERBB2, ERBB3, ABL1 L3MBTL1 3696/4885KMT2A 1693/4885POLB 2618/4885
US-20070088044-A1 Quinazoline derivatives as antitumor agents ERBB2, EGFR, ERBB4 L3MBTL1 4594/4885KMT2A 1786/4885POLB 2324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.